Novel Liver-targeted conjugates of Glycogen Phosphorylase Inhibitor PSN-357 for the Treatment of Diabetes: Design, Synthesis, Pharmacokinetic and Pharmacological Evaluations
Authors:
Open Access
- 22 February 2017
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , srep42251
Abstract
PSN-357, an effective glycogen phosphorylase (GP) inhibitor for the treatment for type 2 diabetics, is hampered in its clinical use by the poor selectivity between the GP isoforms in liver and in skeletal muscle. In this study, by the introduction of cholic acid, 9 novel potent and liver-targeted conjugates of PSN-357 were obtained. Among these conjugates, conjugate 6 exhibited slight GP inhibitory activity (IC50 = 31.17 μM), good cellular efficacy (IC50 = 13.39 μM) and suitable stability under various conditions. The distribution and pharmacokinetic studies revealed that conjugate 6 could redistribute from plasma to liver resulting in a considerable higher exposure of PSN-357 metabolizing from 6 in liver (AUCliver/AUCplasma ratio was 18.74) vs that of PSN-357 (AUCliver/AUCplasma ratio was 10.06). In the in vivo animal study of hypoglycemia under the same dose of 50 mg/kg, conjugate 6 exhibited a small but significant hypoglycemic effects in longer-acting manners, that the hypoglycemic effects of 6 is somewhat weaker than PSN-357 from administration up to 6 h, and then became higher than PSN-357 for the rest time of the test. Those results indicate that the liver-targeted glycogen phosphorylase inhibitor may hold utility in the treatment of type 2 diabetes.Keywords
This publication has 17 references indexed in Scilit:
- Development of Novel Bisphosphonate Prodrugs of Doxorubicin for Targeting Bone Metastases That Are Cleaved pH Dependently or by Cathepsin B: Synthesis, Cleavage Properties, and Binding Properties to Hydroxyapatite As Well As Bone MatrixJournal of Medicinal Chemistry, 2012
- Ligand-based modelling followed by synthetic exploration unveil novel glycogen phosphorylase inhibitory leadsBioorganic & Medicinal Chemistry, 2011
- Design, synthesis, and antitumor activity of bile acid–polyamine–nucleoside conjugatesBioorganic & Medicinal Chemistry Letters, 2007
- Design and synthesis of fluconazole/bile acid conjugate using click reactionTetrahedron, 2006
- The Experimental Type 2 Diabetes Therapy Glycogen Phosphorylase Inhibition Can Impair Aerobic Muscle Function During Prolonged ContractionDiabetes, 2006
- Polymer–drug conjugates: Progress in polymeric prodrugsProgress in Polymer Science, 2006
- Glycogen phosphorylase inhibition as a therapeutic target: a review of the recent patent literatureExpert Opinion on Therapeutic Patents, 2006
- 5-Chloroindoloyl glycine amide inhibitors of glycogen phosphorylase: synthesis, in vitro, in vivo, and X-ray crystallographic characterizationBioorganic & Medicinal Chemistry Letters, 2005
- Liver-Selective Glucocorticoid Antagonists: A Novel Treatment for Type 2 DiabetesJournal of Medicinal Chemistry, 2004
- The Family of Glycogen Phosphorylases: Structure and FunctioCritical Reviews in Biochemistry and Molecular Biology, 1989